JP2015501840A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501840A5
JP2015501840A5 JP2014547353A JP2014547353A JP2015501840A5 JP 2015501840 A5 JP2015501840 A5 JP 2015501840A5 JP 2014547353 A JP2014547353 A JP 2014547353A JP 2014547353 A JP2014547353 A JP 2014547353A JP 2015501840 A5 JP2015501840 A5 JP 2015501840A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
seq
sequence encoding
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547353A
Other languages
English (en)
Japanese (ja)
Other versions
JP6333730B2 (ja
JP2015501840A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/069017 external-priority patent/WO2013090296A1/en
Publication of JP2015501840A publication Critical patent/JP2015501840A/ja
Publication of JP2015501840A5 publication Critical patent/JP2015501840A5/ja
Application granted granted Critical
Publication of JP6333730B2 publication Critical patent/JP6333730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547353A 2011-12-12 2012-12-11 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 Active JP6333730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569600P 2011-12-12 2011-12-12
US61/569,600 2011-12-12
PCT/US2012/069017 WO2013090296A1 (en) 2011-12-12 2012-12-11 Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018084090A Division JP6803354B2 (ja) 2011-12-12 2018-04-25 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法

Publications (3)

Publication Number Publication Date
JP2015501840A JP2015501840A (ja) 2015-01-19
JP2015501840A5 true JP2015501840A5 (https=) 2016-01-21
JP6333730B2 JP6333730B2 (ja) 2018-05-30

Family

ID=48613120

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014547353A Active JP6333730B2 (ja) 2011-12-12 2012-12-11 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP2018084090A Active JP6803354B2 (ja) 2011-12-12 2018-04-25 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP2020198052A Active JP7129106B2 (ja) 2011-12-12 2020-11-30 改善されたil-12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP2022129334A Withdrawn JP2022160704A (ja) 2011-12-12 2022-08-15 改善されたil-12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP2024109421A Pending JP2024138373A (ja) 2011-12-12 2024-07-08 改善されたil-12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018084090A Active JP6803354B2 (ja) 2011-12-12 2018-04-25 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP2020198052A Active JP7129106B2 (ja) 2011-12-12 2020-11-30 改善されたil-12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP2022129334A Withdrawn JP2022160704A (ja) 2011-12-12 2022-08-15 改善されたil-12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP2024109421A Pending JP2024138373A (ja) 2011-12-12 2024-07-08 改善されたil-12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法

Country Status (12)

Country Link
US (4) US9272024B2 (https=)
EP (2) EP3336096A1 (https=)
JP (5) JP6333730B2 (https=)
KR (5) KR102277469B1 (https=)
CN (1) CN104245719B (https=)
AU (1) AU2012352457B2 (https=)
BR (1) BR112014014078A2 (https=)
CA (1) CA2858893A1 (https=)
EA (1) EA026926B1 (https=)
MX (2) MX354986B (https=)
WO (1) WO2013090296A1 (https=)
ZA (1) ZA201404199B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6333730B2 (ja) 2011-12-12 2018-05-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
KR20150128900A (ko) 2013-03-15 2015-11-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-23을 갖는 백신
MX383277B (es) * 2015-01-09 2025-03-13 Oncosec Medical Inc Plasmido que codifica a un agonista coestimulador.
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
SI3458083T1 (sl) 2016-05-18 2023-03-31 Modernatx, Inc. Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
WO2017209053A1 (ja) 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
CN106520779A (zh) * 2016-11-09 2017-03-22 华南农业大学 一种通过密码子优化鸡il‑2基因提高鸡的il‑2蛋白表达效率的方法
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
EP3858369A4 (en) 2018-09-26 2022-07-20 Astellas Pharma Inc. Cancer therapy where oncolytic vaccinia virus and immune checkpoint inhibitor are used in combination, and pharmaceutical composition and combination drug used therein
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
KR20220128607A (ko) 2019-09-18 2022-09-21 인터갈락틱 테라퓨틱스, 인크. 합성 dna 벡터 및 사용 방법
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
US20230000969A1 (en) * 2019-10-24 2023-01-05 Inovio Pharmaceuticals, Inc. Improved vaccines for recurrent respiratory papillomatosis and methods for using the same
CN110777115B (zh) * 2019-11-21 2020-08-21 北京启辰生生物科技有限公司 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
WO2023114775A2 (en) * 2021-12-13 2023-06-22 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising multi-subunit cytokines
US20240041939A1 (en) * 2021-12-17 2024-02-08 William Marsh Rice University Encapsulated cells expressing il-12 and uses thereof
CN116621965A (zh) * 2022-05-06 2023-08-22 珠海丽凡达生物技术有限公司 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
CN119256082A (zh) * 2022-05-27 2025-01-03 北京天一方生物科技发展有限公司 一种恒定地产生IL-12p70的增殖性髓样细胞的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
WO1990010693A1 (en) 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
ES2090129T3 (es) 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
HU219767B (hu) 1993-01-26 2001-07-30 Leslie R. Coney Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
JP2001503258A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド 遺伝子発現および搬送系および用途
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
CA2323604A1 (en) * 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US20030181405A1 (en) * 1999-03-12 2003-09-25 Nordstrom Jeffrey L. Interferon alpha plasmids and delivery systems, and methods of making and using the same
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
MXPA05004860A (es) 2002-11-04 2005-08-18 Advisys Inc Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas.
WO2004108260A2 (en) 2003-05-30 2004-12-16 Advisys, Inc. Devices and methods for biomaterial production
CN1798502A (zh) * 2003-05-30 2006-07-05 南佛罗里达大学 治疗恶性肿瘤的方法
US7833754B2 (en) * 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
US8586055B2 (en) * 2007-01-12 2013-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA immunization protocols
WO2010126766A1 (en) * 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
JP6333730B2 (ja) 2011-12-12 2018-05-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
TWI548337B (zh) 2015-10-16 2016-09-01 技嘉科技股份有限公司 散熱模組、顯示卡組件及電子裝置

Similar Documents

Publication Publication Date Title
JP2015501840A5 (https=)
JP2014507146A5 (https=)
JP2015501656A5 (https=)
JP2009544333A5 (https=)
JP2022023102A (ja) 新規多価ナノ粒子に基づくワクチン
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
JP2014502156A5 (https=)
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
JP2019506175A5 (https=)
BRPI0417509A (pt) molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira
JP2012515557A5 (https=)
JP2014534202A5 (https=)
JP2017532966A5 (https=)
JP2013507907A5 (https=)
JP2019530462A5 (https=)
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
RU2015135890A (ru) Композиция вакцины
JP2016533332A5 (https=)
JP2009540801A5 (https=)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
MX2021015465A (es) Vacuna para fiebre porcina africana.
JP2015506705A5 (https=)
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
JP2014519817A5 (https=)
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses